CellulaREvolution Edges Closer To Commercial Launch With New $2.38 Million Pre-Series A Investment Round
Cell cultivation technology
CellulaREvolution has announced the closure of a new funding round. Having netted £1.75 million in a pre-Series A, the British biotech intends to accelerate the development of its continuous cell cultivation technology. This will be used to usher in cultivated meat as a viable and affordable product, within a reasonable timescale. Hong Kong-based Happiness Capital led the investment round, with Allusion One also participating.
New funding follows on from a seed investment round in January 2021 which saw £1.2 million raised. R&D continuation, plus a bolstered commercial team are top priorities for CellulaREvolution. The latter will provide support when in-house bioreactor technology is released to market. The tech will provide a potential solution to cultivated meat manufacturers who struggle to reach price parity with conventional products. It has biologics and cell therapeutics potential as well, allowing for future broad market share.
